Vittorio Rosti Selected Research

Polycythemia Vera

1/2021	Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.
10/2019	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
2/2017	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.
1/2016	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
10/2012	A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation.
3/2012	Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.
3/2009	Novel strategies for patients with chronic myeloproliferative disorders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vittorio Rosti Research Topics

Disease

28	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 08/2005
26	Neoplasms (Cancer) 05/2023 - 03/2009
8	Splenomegaly 01/2022 - 12/2007
7	Polycythemia Vera 01/2021 - 03/2009
6	Anemia 01/2022 - 02/2010
5	Thrombosis (Thrombus) 01/2022 - 03/2009
5	Essential Thrombocythemia 01/2020 - 03/2009
5	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2019 - 03/2005
4	Disease Progression 01/2022 - 08/2014
4	Myocardial Infarction 01/2021 - 08/2007
3	Leukemia 05/2023 - 03/2012
3	Fibrosis (Cirrhosis) 11/2019 - 01/2012
3	Myeloproliferative Disorders (Myeloproliferative Disorder) 10/2019 - 08/2005
3	Inflammation (Inflammations) 12/2018 - 02/2010
3	Infarction (Infarctions) 05/2015 - 02/2011
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019 - 01/2013
2	Renal Cell Carcinoma (Grawitz Tumor) 12/2018 - 02/2014
2	Breast Neoplasms (Breast Cancer) 11/2017 - 01/2014
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2023
1	Myeloid Leukemia (Leukemia, Myelocytic) 05/2023
1	Thrombocytopenia (Thrombopenia) 02/2021
1	Adenocarcinoma 03/2020
1	Hypoxia (Hypoxemia) 11/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 11/2019
1	Wilms Tumor (Wilm's Tumor) 01/2019
1	Hyperplasia 01/2019
1	Kidney Neoplasms (Kidney Cancer) 12/2018
1	Genomic Instability 12/2018
1	Pathologic Complete Response 01/2018
1	Hemangioma (Angioma) 02/2016
1	Liver Neoplasms (Liver Cancer) 01/2016
1	Wounds and Injuries (Trauma) 01/2016
1	Glioblastoma (Glioblastoma Multiforme) 01/2014

Drug/Important Bio-Agent (IBA)

8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 09/2007
6	Hemoglobins (Hemoglobin)IBA 01/2018 - 12/2007
5	Proteins (Proteins, Gene)FDA Link 05/2023 - 03/2005
5	CytokinesIBA 05/2023 - 09/2007
5	ruxolitinibIBA 03/2020 - 03/2009
4	Janus Kinase 2IBA 01/2021 - 03/2009
4	InterferonsIBA 10/2019 - 09/2007
3	C-Reactive ProteinIBA 01/2022 - 01/2016
3	Fibronectins (Fibronectin)IBA 01/2022 - 01/2016
3	CalreticulinIBA 01/2020 - 08/2014
3	erucylphosphocholineIBA 09/2015 - 01/2012
3	Erythropoietin FDA Link 02/2011 - 08/2007
2	AntigensIBA 05/2023 - 01/2019
2	human extra domain A fibronectinIBA 01/2022 - 01/2019
2	Chemokine ReceptorsIBA 01/2021 - 05/2007
2	Conditioned Culture MediaIBA 01/2021 - 05/2015
2	CholesterolIBA 11/2019 - 01/2012
2	Hydroxyurea (Hydrea)FDA LinkGeneric 10/2019 - 01/2016
2	Thrombopoietin (c-mpl Ligand)IBA 01/2019 - 09/2007
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2017 - 02/2014
2	IronIBA 06/2013 - 02/2010
2	Transforming Growth Factors (Transforming Growth Factor)IBA 04/2013 - 01/2011
2	pomalidomideIBA 03/2012 - 07/2011
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2010 - 09/2007
1	Peptides (Polypeptides)IBA 05/2023
1	NucleophosminIBA 05/2023
1	NucleotidesIBA 10/2021
1	Biomarkers (Surrogate Marker)IBA 09/2021
1	ChemokinesIBA 05/2021
1	OMS 2017IBA 02/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2021
1	givinostatIBA 01/2021
1	RNA Splicing FactorsIBA 01/2021
1	CalciumIBA 01/2020
1	Extracellular Matrix ProteinsIBA 11/2019
1	peginterferon alfa-2a (Pegasys)FDA Link 10/2019
1	romiplostim FDA Link 01/2019
1	Protein Isoforms (Isoforms)IBA 01/2019
1	Interleukin-6 (Interleukin 6)IBA 01/2019
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019
1	MTOR InhibitorsIBA 12/2018
1	Angiogenesis InhibitorsIBA 12/2018
1	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 10/2017
1	CollagenIBA 10/2017
1	TrabectedinIBA 01/2017
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2016
1	Nicotinamide PhosphoribosyltransferaseIBA 01/2016
1	Janus Kinase 1IBA 01/2016
1	Angiopoietin-2IBA 01/2016
1	TIE-2 Receptor (Receptor, TIE 2)IBA 01/2016
1	Tyrosine Kinase InhibitorsIBA 01/2015
1	MicroRNAs (MicroRNA)IBA 09/2014
1	Messenger RNA (mRNA)IBA 09/2014
1	Transient Receptor Potential ChannelsIBA 02/2014
1	CreatinineIBA 10/2013

Therapy/Procedure

13	Therapeutics 05/2023 - 12/2007
5	Drug Therapy (Chemotherapy) 05/2023 - 12/2009
4	Splenectomy 01/2016 - 12/2007
2	Transplantation 01/2019 - 01/2018
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2019 - 09/2010
2	Percutaneous Coronary Intervention 10/2013 - 02/2011
1	Immunotherapy 05/2023
1	Hematopoietic Stem Cell Mobilization 01/2022
1	Stem Cell Transplantation 01/2019
1	Molecular Targeted Therapy 01/2015
1	Aftercare (After-Treatment) 01/2014
1	Ischemic Postconditioning 10/2013